Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$4.09-3.76%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Manage operating losses and cash burn: TTM operating cash flow -$17.7M vs target -$19.5M.
Relmada is advancing Phase 2 trials for NDV-01. The trial showed a 76% complete response rate at 12 months. The company manages cash burn and operating losses carefully. They raised capital through private placement to fund development.
Relmada keeps losing money with no profit in sight. EPS is expected to stay negative through 2026. The company faces ongoing cash burn and operating losses. Clinical trial success is not guaranteed.
The market prices in ongoing losses and clinical risks. There is no clear consensus on revenue or profit growth. Our view is cautious given the speculative nature of the turnaround.
Breaks if: Operating losses worsen beyond -$19.5M in 2026-Q1
Control operating expenses and cash burn while advancing clinical programs to extend cash runway.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on advancing clinical programs. The current thesis state is cautious, reflecting recent mixed signals and elevated risk factors.
The market appears to have low expectations for RLMD, given its loss-making status and weak recent financial performance compared to peers. Investors may be pricing in a challenging environment, especially if guidance is cut or economic conditions worsen.
Fundamentals may remain weak in the near term due to elevated risk and fragile earnings quality. Management is focused on advancing the NDV-01 program, but recent earnings surprises have been erratic, indicating potential volatility ahead.
The thesis hinges on key factors such as the performance of sector bellwethers, the success of the NDV-01 program, and broader economic conditions impacting healthcare names. Any guidance changes or shifts in the jobs report could significantly affect sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Net loss decreased from $19.1 million in 2026-Q1 to $12.9 million in 2026-Q2. Net cash used in operating activities declined from $15.1 million to $9.6 million over the same period. Management continues to focus on managing operating losses and cash burn. The trajectory shows limited progress with reduced losses and cash burn.
“Net loss for Q2 2026 was $12.9 million; net cash used in operating activities was $9.6 million.”
“Net loss for Q1 2026 was $19.1 million; net cash used in operating activities was $15.1 million.”
Breaks if: Failure to initiate Phase 2 PWS study or negative 12-month data
Breaks if: Failure to secure needed funding through private placement
Over the next 1 to 3 years, RLMD's prospects will depend on its clinical advancements and external economic factors. Not investment advice.